Cancer reports最新文献

{"title":"A Comprehensive Analysis of Epoxide Hydrolase 2 (EPHX2) in Pan-Cancer","authors":"Weiquan Hu,&nbsp;Xiaoli Ding,&nbsp;Xiangsheng Wu,&nbsp;Xuxiang Xi,&nbsp;Jing Xu,&nbsp;Shengyun Dai,&nbsp;Jing Chen,&nbsp;Suping Hu,&nbsp;Qinfei Zhao,&nbsp;Fangfang Chen","doi":"10.1002/cnr2.70188","DOIUrl":"https://doi.org/10.1002/cnr2.70188","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Epoxide hydrolase 2 (EPHX2) regulates lipid signaling across various metabolites by encoding soluble epoxide hydrolase. However, its mechanisms and implications in human malignancies remain unknown. This research aimed to detail the prognostic landscape of EPHX2 in pan-cancer and explore its potential relationship with immune infiltration in the tumor microenvironment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Herein, multiple bioinformatics tools were used to comprehensively evaluate the expression, diagnostic, and prognostic significance of EPHX2 and its roles in the tumor immune microenvironment in human cancers. The underlying EPHX2-associated signaling pathways in cancers were investigated by gene set variation analysis (GSVA). TIDE, GDSC, and CTRP databases were applied to predict the response of EPHX2 to immunotherapy and sensitivity to small molecule drugs. Furthermore, EPHX2 expression was also validated by qPCR experiments in various cancer cell lines.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall results revealed significant down-regulation of EPHX2 mRNA expression in most tumors. Despite its high predictive significance across cancers, EPHX2 played a protective or detrimental effect in distinct types of cancers. EPHX2 proved to be a valuable diagnostic biomarker in a range of tumor types, particularly in kidney renal clear cell carcinoma, cervical squamous cell carcinoma, and endocervical adenocarcinoma. Genetic alterations of EPHX2 in 33 tumors were also investigated. EPHX2 expression was significantly linked to immune cell infiltrations (particularly tumor-associated macrophages), tumor mutation burden, microsatellite instability, immune modulators, and immunotherapeutic biomarkers. Single-cell sequencing and GSVA highlighted the relevance of EPHX2 in regulating various cancer-related biological processes, including cell cycle and apoptosis. In this view, targeting EPHX2-dependent signaling could be a promising therapeutic strategy for tumor immunotherapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>EPHX2 may serve as a potential molecular biomarker for diagnosis and prognosis in pan-cancer and could become a novel therapeutic target for various cancers.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 3","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70188","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Usability of a Clinical Decision Support System for Cancer Care: A User-Centered Study","authors":"Darya Chyzhyk,&nbsp;Maddi Arregi,&nbsp;Maria Errazquin,&nbsp;Ainhoa Ariceta,&nbsp;Macarena Sevilla,&nbsp;Roberto Álvarez,&nbsp;Maider Alberich Inchausti","doi":"10.1002/cnr2.70173","DOIUrl":"10.1002/cnr2.70173","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Adverse effects are a common burden for cancer patients, impacting their well-being and diminishing their quality of life. Therefore, it is essential to have a clinical decision support system that can proactively monitor patient progress to prevent and manage complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This research aims to thoroughly test the usability and user-friendliness of a medical device designed for managing adverse events for cancer patients and healthcare professionals (HCPs). The study seeks to assess how well the device meets both patients' and HCPs' needs in real-world scenarios.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>The study used a multi-method approach to obtain a comprehensive understanding of participants experience and objective measure of usability. The testing was conducted with a diverse group of participants of six patients and six HCPs. Analysis included a descriptive summary of the demographic data, scenario completion rates, System Usability Scale (SUS) questionnaire score, and qualitative feedback from users. All participants successfully completed 100% of the activities, indicating a high level of understanding and usability across both user groups. Only two out of six patients encountered errors during the login activities, but these errors were unrelated to product safety. The obtained SUS score is in the 90th percentile for both user groups, classifying the device as grade A and highlighting its superior usability. Patients and HCPs found the interface intuitive and expressed an interest in incorporating the application into their daily routines and would recommend the application to others.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The assessed digital health medical device demonstrates excellent usability, safety, and ease of use for oncology patients and HCPs. Based on the received constructive feedback, minor improvements were identified for further refinement of the application that do not affect either its intended functionality or the overall functioning of the tool. Future work will focus on implementing these improvements and conducting further usability studies in clinical environments.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 3","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924132/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing the Effectiveness of Artificial Intelligence Models in Predicting Ovarian Cancer Survival: A Systematic Review","authors":"Farkhondeh Asadi,&nbsp;Milad Rahimi,&nbsp;Nahid Ramezanghorbani,&nbsp;Sohrab Almasi","doi":"10.1002/cnr2.70138","DOIUrl":"https://doi.org/10.1002/cnr2.70138","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This systematic review investigates the use of machine learning (ML) algorithms in predicting survival outcomes for ovarian cancer (OC) patients. Key prognostic endpoints, including overall survival (OS), recurrence-free survival (RFS), progression-free survival (PFS), and treatment response prediction (TRP), are examined to evaluate the effectiveness of these algorithms and identify significant features that influence predictive accuracy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Recent Findings</h3>\u0000 \u0000 <p>A thorough search of four major databases—PubMed, Scopus, Web of Science, and Cochrane—resulted in 2400 articles published within the last decade, with 32 studies meeting the inclusion criteria. Notably, most publications emerged after 2021. Commonly used algorithms for survival prediction included random forest, support vector machines, logistic regression, XGBoost, and various deep learning models. Evaluation metrics such as area under the curve (AUC) (18 studies), concordance index (C-index) (11 studies), and accuracy (11 studies) were frequently employed. Age at diagnosis, tumor stage, CA-125 levels, and treatment-related factors were consistently highlighted as significant predictors, emphasizing their relevance in OC prognosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>ML models demonstrate considerable potential for predicting OC survival outcomes; however, challenges persist regarding model accuracy and interpretability. Incorporating diverse data types—such as clinical, imaging, and molecular datasets—holds promise for enhancing predictive capabilities. Future advancements will depend on integrating heterogeneous data sources with multimodal ML approaches, which are crucial for improving prognostic precision in OC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 3","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70138","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143645718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Incidental Giant Intraductal Papilloma Containing Ductal Carcinoma In Situ","authors":"Micaela Resta,&nbsp;Stephanie Fine","doi":"10.1002/cnr2.70184","DOIUrl":"https://doi.org/10.1002/cnr2.70184","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Intraductal papillomas of the breast (IDPs) are typically small benign lesions characterized by pathologic discharge, a palpable mass, or an occult presentation. Giant IDPs (&gt; 5 cm) are a rare entity. The few existing cases of giant IDPs describe grossly apparent exam findings and concerning features on imaging. While surgical excision is the standard of care for most IDPs, there is a scarcity of evidence to guide management of giant papillary tumors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>We describe a case of a 64-year-old female presenting with pathologic nipple discharge and no discrete palpable breast mass who was routinely diagnosed with ductal carcinoma in situ (DCIS). Imaging findings of mass calcifications and intraductal mass debris correlated with biopsy results, and the patient underwent central lumpectomy with oncoplastic reconstruction. At the time of surgery, the DCIS was incidentally found to be contained within a large solitary papilloma. The specimen pathology showed DCIS spanning a large area in a multifocal pattern that involved a 7 cm giant intraductal papilloma. Though margins were negative for malignancy, the benign papillary lesion was incompletely excised. A multidisciplinary review opted to pursue whole breast radiation therapy followed by adjuvant endocrine treatment over re-excision.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This unusual case highlights the potential for giant IDP to remain clinically occult in the background of known ductal carcinoma in situ and emphasizes the value of multidisciplinary care discussion and a patient-centered approach to surgical decision making in the absence of existing guidelines.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 3","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70184","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143645752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast Cancer Awareness, Screening Practices, and Perceived Barriers Among Female Undergraduate Students: An Institution-Based Cross-Sectional Study","authors":"Md. Mayin Uddin Hasan,&nbsp;Mohammad Injamul Hoq,&nbsp;Rijuana Ireen Tanju,&nbsp;Md. Jakaria,&nbsp;Mohammed Abu Sayeed","doi":"10.1002/cnr2.70187","DOIUrl":"https://doi.org/10.1002/cnr2.70187","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Breast cancer is a significant worldwide public health issue that poses a substantial threat to the lives of countless people around the world. Increasing awareness and implementing screening for breast cancer are two of the crucial strategies for decreasing the burden of disease. The study assessed awareness, practice, and perceived barriers to breast cancer screening among university students.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Method&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;An institution-based cross-sectional study was conducted from June 2023 to December 2023 at the International Islamic University Chittagong (IIUC), Bangladesh, where 387 students were randomly selected for this study.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Result&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Among 387 participants, the majority (25.06%) were from the faculty of business administration, whereas 23.51% were from the faculty of science and engineering. Most (80.41%) of respondents had sufficient awareness of breast cancer and its screening. While they were aware of breast cancer screening, majority (67.7%) did not practice it. Students of law faculty were about three times [AOR: 0.31 (95% CI: 0.118–0.828)] and students of business administration faculty were about five times [AOR: 0.21 (95% CI: 0.087–0.532)] less likely to be aware of breast cancer and Breast Self Examination (BSE) than faculty of science and engineering. Also, living in dormitory students were more than two times [AOR: 0.42 (95% CI: 0.189–0.940)] less likely to be aware of breast cancer and screening of breast than those living with family. The majority (52.2% to 79.33%) of the students did not correctly identify different warning signs of breast cancer. Perceptions of having “no signs &amp; symptoms,” not having “sufficient organization working on screening,” and “lack of awareness program” were found to be leading barriers to breast screening among students.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Though better awareness about breast cancer and its screening was found among the students, low practices were observed in screening. Students of the science and engineering faculty demonstrated a sufficient level of breast cancer awareness than students from other faculties, and students with good screening practice habits of breast cancer were sufficiently aware of breast cancer than poorly practicing students. Still, warning signs of breast cancer are unfamiliar to female students among university students. Frequent awareness campaigns are essential to train the students at regular intervals.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 ","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 3","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70187","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioinformatics Analysis of the Expression and Prognostic Significance of Transcription Factor YY1 in Gastric Cancer","authors":"Wenliang Chen,&nbsp;Huanhuan Wang,&nbsp;Ntiak Achi,&nbsp;Jinjin Hao,&nbsp;Rui Gong,&nbsp;Qiang Zhao","doi":"10.1002/cnr2.70181","DOIUrl":"https://doi.org/10.1002/cnr2.70181","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Emerging evidence indicates that the transcription factor Yin Yang 1 (YY1) plays a critical role in the carcinogenesis and progression of various human malignancies. YY1 is highly expressed in gastric cancer (GC), raising interest in its role in GC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aims to analyze the role of YY1 in gastric cancer, investigate its effect on the tumor microenvironment, and assess its potential as a prognostic marker.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Transcriptomic data and clinical information from GC patients were obtained from the TCGA and UCSC databases. YY1 expression was analyzed using the R “limma” package. Gene ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed with the online tool clusterProfiler. The relationship between YY1 expression levels and the tumor microenvironment was examined in different risk groups of GC patients. Additionally, YY1-positive staining in 26 clinical GC samples was measured using ImageJ software. Co-expression analysis was used to identify prognostic genes associated with YY1, and a prognostic risk model was built and optimized.</p>\u0000 \u0000 <p>Results showed that YY1 was significantly overexpressed in 415 GC (<i>p</i> &lt; 0.001) and was associated with poorer survival outcomes (<i>p</i> = 0.043). GO and KEGG showed that YY1 was involved in key biological processes of the disease. Higher YY1 expression was correlated with lower stromal and immune cell content in the tumor microenvironment. Immunohistochemical staining confirmed YY1 overexpression in GC tissues compared to normal tissues (<i>p</i> = 0.0293). Positive correlations were observed between YY1 and the genes MTA1, TTL15, HNRNPU, WDR20, and PPP4R3A. The prognostic model, which included genes significantly associated with YY1 (risk score AUC = 0.690), predicted patient survival better than other clinical variables.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These findings suggest that YY1 plays an important role in the development of GC. Targeting the YY1 pathway may be a potential treatment strategy for GC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 3","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70181","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143629831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research Progress on the Role of Zinc Finger Protein in Colorectal Cancer","authors":"Tang Yu,&nbsp;Jiumei Zhao,&nbsp;Ziwei Li,&nbsp;Chenglong Pan,&nbsp;Jialing Liu,&nbsp;Kepu Zheng,&nbsp;Xiaohao Wang,&nbsp;Yan Zhang","doi":"10.1002/cnr2.70123","DOIUrl":"https://doi.org/10.1002/cnr2.70123","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Colorectal cancer is one of the most prevalent malignancies worldwide, with a tendency of increasing incidence in developed countries, which poses a significant threat to the patients' physical and mental health.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Recent Findings</h3>\u0000 \u0000 <p>The process of gene transcription affects the important physiological functions of cells, so the normal expression of transcription factors is an important prerequisite for maintaining cellular homeostasis. Changes in the level of zinc finger proteins, the most prevalent transcription factor, may play an important trigger for the development of colorectal cancer. Different zinc finger proteins play different roles in terms of promoting or inhibiting cancer development.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This paper briefly reviews the classification, functional characteristics, and expression changes of zinc finger proteins in colorectal cancer, it focuses on how they regulate gene transcription, influence on common signaling pathways, and their potential for translational studies and clinical applications. The objective is to stimulate new ideas for their study of colorectal cancer while also providing foundational information to guide drug development and treatment strategies for colorectal cancer patients in clinical settings.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 3","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70123","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143622403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics and Prognostic Markers of Aggressive Subtypes of Thyroid Cancer: A Retrospective Study","authors":"Suhaib Radi,&nbsp;Mazin Al-Maghrabi,&nbsp;Saleh Binmahfooz,&nbsp;Miguel Franco,&nbsp;Richard Payne,&nbsp;Michael Tamilia","doi":"10.1002/cnr2.70131","DOIUrl":"https://doi.org/10.1002/cnr2.70131","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The prevalence of thyroid cancer has increased significantly. Aggressive subtypes of papillary thyroid cancer (AG-PTC) and high-grade follicular cell-derived malignancies (HGFM) are malignancies that lie between well-differentiated and undifferentiated cancers, and their management needs to be clarified. The aim of our study is to describe the clinicopathological characteristics of AG-PTC and HGFM and to assess their prognostic value.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a retrospective chart review study at single center of patients with AG-PTC or HGFM. HGFM comprised of patients with poorly differentiated thyroid cancer (PDTC) and differentiated high-grade thyroid carcinoma. The clinical presentation, pathological characteristics, molecular markers, specific treatments, and clinical outcomes were compared between the groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 3244 thyroid cancer charts reviewed, 136 met the criteria for AG-PTC and HGFM. The mean age at diagnosis was 49 years, with a predominance of women. The median follow-up duration was 3 years. The rate of persistent or recurrent disease was 40.3% in the AG-PTC group and 29.3% in the HGFM group, 4.5% died in the AG-PTC group, and 1.8% died in the HGFM group. The presence of vascular, lymphovascular invasion and extrathyroidal extension were associated with a higher incidence of persistent or recurrent disease (Hazard ratio: 2.5, 3.8, and 4.2, respectively; <i>p</i> &lt; 0.05). When the Ki-67 index was divided into five groups, the recurrence rate was higher in the ≥ 20% Ki-67 group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Possible prognostic markers for predicting worse prognosis include vascular/lymphovascular invasion, extrathyroidal extension, and the proliferative index Ki-67.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 3","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70131","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143622404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inotuzumab Ozogamicin as a Bridge to Stem Cell Transplantation in Relapsed Pediatric BCP-ALL After Tisagenlecleucel: A Case Series","authors":"Margo Aertgeerts,&nbsp;Marleen Renard,&nbsp;Anne Uyttebroeck,&nbsp;Nancy Boeckx,&nbsp;Heidi Segers","doi":"10.1002/cnr2.70177","DOIUrl":"https://doi.org/10.1002/cnr2.70177","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>CD19-directed chimeric antigen receptor T-cell therapy tisagenlecleucel has shown promising results in the treatment of pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, around 50% of patients relapse after tisagenlecleucel. Following multiple relapses, limited treatment options are left, and the prognosis is dismal. We report on four pediatric patients who relapsed after tisagenlecleucel and were treated with inotuzumab ozogamicin (InO).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>Four patients with BCP-ALL received tisagenlecleucel after second relapse (3/4) or refractory disease at first relapse (1/4). Three patients relapsed with CD19^NEG/CD22^POS BCP-ALL, one with CD19^POS/CD22^POS BCP-ALL. Following relapse, they received treatment with InO. After the first InO cycle, all achieved complete remission (CR), three without measurable residual disease. After two or three InO cycles, they underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). One patient developed an isolated extramedullary relapse (IEM) in both anterior eye chambers six and nine months after allo-HSCT and received palliative radiotherapy. This patient was in CR at the last follow-up 25 months later. The other patients were also in CR at the last follow-up (mean 31.3 months).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>InO can be used successfully and safely for the treatment of CD22^POS BCP-ALL relapse after tisagenlecleucel as a bridge to allo-HSCT in heavily pretreated pediatric patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 3","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70177","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143622405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spleen Involvement at Diagnosis of Multiple Myeloma: A Case Report and Literature Review","authors":"Alessia Fiorini,&nbsp;Maria Gabriela Chavez,&nbsp;Valentina Panichi,&nbsp;Marco Dell'Aquila,&nbsp;Valentina Ranucci,&nbsp;Daniele Remotti,&nbsp;Michela Tarnani,&nbsp;Marco Montanaro,&nbsp;Roberto Latagliata,&nbsp;Alessandro Andriani","doi":"10.1002/cnr2.70160","DOIUrl":"https://doi.org/10.1002/cnr2.70160","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Multiple myeloma (MM) is more often characterized by clonal plasma cell proliferation restricted to the bone marrow. However, a small percentage of patients with MM develop extramedullary disease (EMD): this type of localization is found in 1.7%–4.5% of the newly diagnosed MM (ND/MM) and in 3.4%–10% of patients with relapsed or refractory disease (RR/MM) and seems to have a bad prognostic impact. In the present report, we describe a very rare case of splenic involvement in a patient with ND/MM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>A 72-year-old female was referred to Santa Rosa Hospital of Viterbo in June 2022 with asthenia and abdominal pain. At physical examination, spleen enlargement was detected, with anemia (Hb 10.5 g/dL) and thrombocytopenia (48 × 10⁹/L). Abdominal echography confirmed spleen enlargement (20 cm of longitudinal diameter). Blood tests showed free light chain alteration with a <i>λ</i>/<i>κ</i> ratio of 800. Marrow aspiration showed 60% of λ-restricted immature plasma cells: p53 expression was present in 91% of elements. Positron emission tomography/computed tomography (PET/CT) scan revealed multiple focal areas of increased metabolic activity in the bones and a widespread positivity of the spleen with focal areas of higher uptake. A diagnosis of MM with splenic EMD was made, and the Dara-VMP regimen (daratumumab, bortezomib, melphalan, and prednisone) was started. After the first cycle of therapy, a marked reduction in spleen size was observed with an increase in both Hb level and platelet count. After the second cycle of therapy, however, there was evolution into plasma cell leukemia: the Vd-PACE regimen (bortezomib, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide) was thus started, but after the second cycle, she died in October 2022 from septic shock and multiorgan failure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our very rare case of ND/MM with spleen involvement confirms the aggressive behaviour of EMD, with negative prognostic factors (p53 mutation) and failure to frontline highly effective therapy. In the other few cases of spleen involvement reported, however, there were only scarce details about response: as a consequence, collection of similar cases is warranted to fully understand clinical features and possible alternative approaches for these extremely rare patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 3","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70160","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143602783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}